XBIT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XB

Mkt Cap

$64.2M

Volume

67.79K

Next Earnings

November 11th

Loading chart

XB

XBITXBiotech Inc

XBIT

Pay with—

Available Balance0.00

XB

Mkt Cap

$64.6M

Volume

67.79K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisXBiotech announced that its IND application for the V-SPINE Phase II clinical trial evaluating vilamakitug (an IL-1α antibody) for treating active axial spondyloarthritis has completed FDA review without a clinical hold. The double-blind, placebo-controlled study will enroll 150 participants and evaluate the drug's efficacy and safety, with the primary endpoint being ASAS40 response at Week 16.GlobeNewswire Inc. · Jun 15, 2026

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities lawsWolf Haldenstein Adler Freeman & Herz LLP is investigating XBiotech for potential securities law violations after the company announced issues with its Phase II rheumatoid arthritis drug study, leading to a 29% stock price drop.GlobeNewswire Inc. · Jan 14, 2025

XBiotech suspend son programme de rhumatologieXBiotech has suspended its clinical program on rheumatological conditions pending a review of the results from its recent Phase II study on rheumatoid arthritis. The study did not meet its primary endpoint due to substantial irregularities, and the company is now evaluating the implications of the results before deciding on the next steps for its Natrunix drug candidate in rheumatology.GlobeNewswire Inc. · Dec 24, 2024

XBiotech setzt Rheumatologieprogramm ausXBiotech has announced that it is halting its clinical program for rheumatological diseases after its recent Phase II trial for rheumatoid arthritis failed to meet its primary endpoint due to significant irregularities that made the results difficult to interpret. The company is now evaluating the data to understand the implications and determine how to proceed with potential future rheumatology studies.GlobeNewswire Inc. · Dec 24, 2024

Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - Long-term Forecast to 2033The global cancer cachexia market is expected to grow from $2.47 billion in 2024 to $3.14 billion by 2028, driven by increased cancer prevalence, enhanced treatment options, and greater awareness among healthcare professionals.GlobeNewswire Inc. · Aug 23, 2024

Ergebnisse aus randomisierter, doppelt verblindeter Phase-I/II-Studie von XBiotech deuten auf mögliche bahnbrechende Behandlung gegen fortgeschrittenen Bauchspeicheldrüsenkrebs hinDie Ergebnisse zeigen Tendenz zu geringeren Toxizitäten und besseren Ergebnissen bei Patienten, die eine Kombination aus ONIVYDE/5-FU und gezielter Anti-IL-1alpha-Therapie erhalten Die Ergebnisse zeigen Tendenz zu geringeren Toxizitäten und besseren Ergebnissen bei Patienten, die eine Kombination aus ONIVYDE/5-FU und gezielter Anti-IL-1alpha-Therapie erhaltenGlobeNewswire Inc. · Jun 19, 2024

Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancéLes données indiquent des tendances vers une réduction des toxicités et de meilleurs résultats pour les sujets recevant l’association ONIVYDE/5-FU et une thérapie ciblée par anti-IL-1alpha Les données indiquent des tendances vers une réduction des toxicités et de meilleurs résultats pour les sujets recevant l’association ONIVYDE/5-FU et une thérapie ciblée par anti-IL-1alphaGlobeNewswire Inc. · Jun 19, 2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerFindings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyGlobeNewswire Inc. · Jun 18, 2024

The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechQuince Therapeutics and XBiotech are included in this Analyst Blog.Zacks Investment Research · Mar 8, 2024

Don't Know Much Biology? Tips for Picking Microcap Biotech, PharmaTwo microcap biotech stocks to consider for the science-challenged among us.Zacks Investment Research · Mar 7, 2024

to start trading

XB

XBITXBiotech Inc

XBIT

Pay with—

Available Balance0.00

Your PositionYou don't own any XBIT yet.

Related Tickers

Earnings